Statin therapy is not associated with improved vascular access outcomes

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 8, 2010, Pages 1447-1450

  Pisoni, Roberto ^a   Barker Finkel, Jill ^b   Allon, Michael ^a  

^a University of Alabama at Birmingham   (United States)

^b MONTANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE; ARTERY DISEASE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; FISTULA; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; SEX DIFFERENCE; VASCULAR ACCESS;

ADULT; AGE FACTORS; AGED; ALABAMA; ARTERIOVENOUS SHUNT, SURGICAL; BLOOD VESSEL PROSTHESIS IMPLANTATION; CHRONIC DISEASE; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; UPPER EXTREMITY;

EID: 77955744310     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02740310     Document Type: Article

References (24)

1. Feldman HI, Kobrin S, Wasserstein A: Hemodialysis vascular access morbidity. J Am Soc Nephrol 7: 523-535, 1996
2. Rayner HC, Pisoni RL, Bommer J, Canaud B, Hecking E, Locatelli F, Piera L, Bragg-Gresham JL, Feldman HI, Goodkin DA, Gillespie B, Wolfe RA, Held PJ, Port FK: Mortality and hospitalization in haemodialysis patients in five European countries: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19: 108-120, 2004 (Pubitemid 38072622)
3. Woods JD, Port FK: The impact of vascular access for haemodialysis on patient morbidity and mortality. Nephrol Dial Transplant 12: 657-659, 1997
4. Maya ID, O'Neal JC, Young CJ, Barker-Finkel J, Allon M: Outcomes of brachiocephalic fistulas, transposed brachio-basilic fistulas, and upper arm grafts. Clin J Am Soc Nephrol 4: 86-92, 2009
5. Roy-Chaudhury P, Kelly BS, Melhem M, Zhang J, Li J, Desai P, Munda R, Heffelfinger SC: Vascular access in hemodialysis: Issues, management, and emerging concepts. Cardiol Clin 23: 249-273, 2005
6. Chang CJ, Ko PJ, Hsu LA, Ko YS, Ko YL, Chen CF, Huang CC, Hsu TS, Lee YS, Pang JHS: Highly increased cell proliferation activity in restenotic hemodialysis vascular access after percutaneous transluminal angioplasty: Implication in prevention of stenosis. Am J Kidney Dis 43: 74-84, 2004
7. Roy-Chaudhury P, Kelly BS, Miller MA, Reaves A, Armstrong J, Nanayakkara N, Heffelfinger SC: Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int 59: 2325-2334, 2001
8. Roy-Chaudhury P, Kelly BS, Zhang J, Narayana A, Desai P, Melham M, Duncan H, Heffelfinger SC: Hemodialysis vascular access dysfunction: From pathophysiology to novel therapies. Blood Purif 21: 99-110, 2003
9. Weiss MF, Scivittaro V, Anderson JM: Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access. Am J Kidney Dis 37: 970-980, 2001
10. Allon M: Current management of vascular access. Clin J Am Soc Nephrol 2: 786-800, 2007
11. Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, Dember LM, Himmelfarb J, Gassman JJ, Greene T, Radeva MK, Davisdson IJ, Ikizler TA, Braden GL, Fenves AZ, Kaufman JS, Cotton JR, Martin KJ, McNeil JW, Rahman A, Lawson JH, Whiting JF, Hu B, Meyers CM, Kusek JW, Feldman HI, for the Dialysis Access Consortium (DAC) Study Group: Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med 360: 2191-2201, 2009
12. Fingerle J, Muller RM, Kuhn H, Pech M, Baumgartner HR: Mechanism of inhibition of neointimal formation by the angiotensin-converting enzyme inhibitor cilazapril. A study in balloon catheter-injured rat carotid arteries. Arterioscler Thromb Vasc Biol 15: 1945-1950, 1995
13. Gibson KD, Caps MT, Kohler TR, Hatsukami TS, Gillen DL, Aldassy M, Sherrard DJ, Stehman-Breen CO: Assessment of a policy to reduce placement of prosthetic hemodialysis access. Kidney Int 59: 2335-2345, 2001
14. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA: Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation 101: 1311-1318, 2000
15. Righetti M, Ferrario G, Serbelloni P, Milani S, Tommasi A: Some old drugs improve late primary patency rate of native arteriovenous fistulas in hemodialysis patients. Ann Vasc Surg 23: 491-497, 2009
16. Saran R, Dykstra DM, Wolfe RA, Gillespie B, Held PJ, Young EW: Association between vascular access failure and the use of specific drugs: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 40: 1255-1263, 2002
17. Robbin ML, Chamberlain NE, Lockhart ME, Gallichio MH, Young CJ, Deierhoi MH, Allon M: Hemodialysis arteriovenous fistula maturity: US evaluation. Radiology 225: 59-64, 2002
18. Singh P, Robbin ML, Lockhart ME, Allon M: Clinically immature arteriovenous hemodialysis fistulas: Effect of US on salvage. Radiology 246: 299-305, 2008
19. Szmitko PE, Fedak PW, Weisel RD, Stewart DJ, Kutryk MJ, Verma S: Endothelial progenitor cells: New hope for a broken heart. Circulation 107: 3093-3100, 2003
20. Vaughan CJ, Gotto AM Jr, Basson CT: The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 35: 1-10, 2000
21. Wiesbauer F, Kaun C, Zorn G, Maurer G, Huber K, Wojta J: HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: A comparative study using different statins. Br J Pharmacol 135: 284-292, 2002
22. Bellosta S, Bernini F, Ferri N, Quarato P, Canavesi M, Arnaboldi L, Fumagalli R, Paoletti R, Corsini A: Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 137[Suppl 1]: S101-S109, 1998
23. Dol F, Mares A, Herbert J: Simvastatin inhibits myointimal hyperplasia following carotid artery injury in cholesterolfed rabbits. Blood Coagul Fibrinolysis 7: 772-778, 1996
24. Chou CY, Kuo HL, Yung YF, Liu YL, Huang CC: C-reactive protein predicts vascular access thrombosis in hemodialysis patients. Blood Purif 24: 342-346, 2006